LabCorp Acquires Covance Genomics Laboratory
LabCorp acquired Covance Genomics Laboratory (CGL) and its associated genomic analysis business.
We are excited to announce LabCorp's acquisition of the Covance Genomics Laboratory (CGL) and its associated genomic analysis business. This state-of-the-art laboratory located in Seattle provides leading-edge complex genomic analysis, including gene expression array studies and next generation sequencing applications, to support drug development activity for pharmaceutical and biotechnology companies. In addition to offering these services to our existing clients, LabCorp and Covance have entered into a five-year services agreement to collaborate and continue offering specialty genomic services to Covance clients.
The platforms and capabilities available at this laboratory are complementary to and broaden LabCorp's existing global Clinical Trials laboratory network, and we will work to develop and expand these capabilities in the future. Equally impressive are the skills and accomplishments of the more than 50 scientists and staff who are now members of the LabCorp team.
In addition to global safety and specialty testing services, LabCorp can now offer clients a more comprehensive set of genomic services in earlier stages of drug development. The acquisition enhances LabCorp's existing biomarker development and companion diagnostics capabilities and it confirms our commitment to expand and enhance our industry-leading genomic services -- including translational biomarkers, computational biology, and next generation sequencing.
LabCorp Clinical Trials already provides a number of core genomic services -- including mutation analysis, pharmacogenetics, and pharmacogenomics -- from our global locations in North America, Belgium and China to support early- to late-phase clinical trials. This acquisition significantly expands our current offering by allowing LabCorp to provide clients with a more comprehensive set of genomic services from preclinical and early development to late-stage development.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
